Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Crohn's Disease: full-pipeline trial registry
37 of 106 indexed Crohn's Disease trials are currently recruiting.
Corpus placement: #122 of 28,707 conditions by registered trial count.
106 US clinical trials · 37 currently recruiting · #122 of 28,707 conditions by registered trial count
Crohn's Disease: 106 US clinical trials tracked, 37 recruiting.
Crohn's Disease is the subject of 106 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 46 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 13 of these trials.
Enrollment posture brief
Registry condition crohns-disease
OPEN 37 | RECR 35% | LATE 46 | EARLY 36 | RANK #122 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Hemophilia A (35% recruiting · 43 trials)
Crohn's Disease lists 37 open slots (35% of 106 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Crohn's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Crohn's Disease is recruiting below its size-band peers.
37 of 106 indexed trials (34.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Crohn's Disease trials is spread across many organizations.
Takeda accounts for 13 of 106 trials (12.3%). 52 distinct sponsors appear on at least one study for this condition label.
-
Typical Crohn's Disease enrolment sits around 196 participants.
Median target enrolment is 196 among the 106 trials that report a genuine target (sentinel values excluded). 36 of those (34%) plan for fewer than 100 participants.
-
Crohn's Disease research is mostly interventional.
90 interventional and 16 observational studies make up this index (84.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
106 total, page 2 of 3
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis
Massachusetts General Hospital
NCT02412553
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
Hoffmann-La Roche
NCT05910528
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
Icahn School of Medicine at Mount Sinai
NCT03992469
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
University Hospitals Cleveland Medical Center
NCT00622557
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company
NCT03926130
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease
Icahn School of Medicine at Mount Sinai
NCT02054533
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Abbott
NCT00077779
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
Abbott
NCT00195715
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Janssen Research & Development
NCT01369329
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Takeda
NCT02611817
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
AbbVie
NCT03345836
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
AbbVie
NCT03345849
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
AbbVie
NCT02065570
Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
University of North Carolina, Chapel Hill
NCT04852666
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
Biogen
NCT00078611
Pregnancy Exposure Registry for Tysabri®
Biogen
NCT00472992
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Tillotts Pharma
NCT00074542
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
University of Maryland, Baltimore
NCT01692743
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
Icahn School of Medicine at Mount Sinai
NCT02322307
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
UCB Pharma
NCT00160706
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
Abbott
NCT00427921
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
Abbott
NCT00055523
Remission in Subjects With Crohn's Disease, 1 Year Phase
Abbott
NCT00055497
A Study To Monitor Long-Term Treatment With PF-00547659
Shire
NCT01298492
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Shield Therapeutics
NCT02680756
Study for the Treatment of Crohn's Disease With Adacolumn
Otsuka America Pharmaceutical
NCT00162942
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Celltrion
NCT02096861
Evaluating a Shared Decision Making Program for Crohn's Disease
Dartmouth-Hitchcock Medical Center
NCT02084290
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
Abbott
NCT00409682
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
Pfizer
NCT01393899
Improving Medication Adherence in Pediatric Inflammatory Bowel Disease
Children's Hospital Medical Center, Cincinnati
NCT01536509
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Pfizer
NCT00615199
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
Bristol-Myers Squibb
NCT01466374
Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
NCT01349504
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Takeda
NCT02425111
FolateScan in Autoimmune Disease
Mayo Clinic
NCT00588393
Dietary Treatment of Crohn's Disease
Rush University Medical Center
NCT00343642
An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
Corewell Health West
NCT00467922
Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography
Mayo Clinic
NCT00819663
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
Biogen
NCT00055536
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda
NCT03196427
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Padagis
NCT01453946
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Amgen
NCT01290042
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
Mayo Clinic
NCT00587041
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Medtronic - MITG
NCT01576120
Induction of Clinical Response Using Rifaximin in Crohn's Disease
Scott Lee
NCT00603616
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease
Indiana University
NCT00586352
Centocor Microarray Study of Patients
University of Rochester
NCT00462072
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
Ferring Pharmaceuticals
NCT00950105
CP-461 for the Treatment of Crohn's Disease
Astellas Pharma
NCT00042055
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 22 |
| Phase 3 | 41 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Crohn's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Crohn's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Crohn's Disease page
106 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Crohn's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Takeda sponsors the most Crohn's Disease trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Crohn's Disease condition card totals 106 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.